^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SSGJ-705
i
Other names: SSGJ-705, 705, SSGJ 705, SSGJ705
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
3SBio
Drug class:
PD1 inhibitor, HER2 inhibitor
Related drugs:
4ms
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov)
P2, N=340, Recruiting, Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting --> Recruiting
Enrollment open
|
SSGJ-705
6ms
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov)
P2, N=340, Not yet recruiting, Shenyang Sunshine Pharmaceutical Co., LTD.
New P2 trial
|
SSGJ-705
over1year
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=180, Recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P1 trial • Metastases
|
SSGJ-705
almost4years
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors (clinicaltrials.gov)
P1, N=162, Not yet recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
SSGJ-705
Share via
